ACADIA Pharmaceuticals (ACAD) Competitors $24.67 +1.06 (+4.49%) Closing price 04:00 PM EasternExtended Trading$24.69 +0.02 (+0.08%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. SMMT, ASND, VTRS, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIVShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences ACADIA Pharmaceuticals (NASDAQ:ACAD) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Does the media refer more to ACAD or SMMT? In the previous week, Summit Therapeutics had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 26 mentions for Summit Therapeutics and 23 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat Summit Therapeutics' score of 0.86 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ACAD or SMMT more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals21.80% 14.69% 9.41% Summit Therapeutics N/A -208.64%-181.28% Do insiders & institutionals hold more shares of ACAD or SMMT? 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, ACAD or SMMT? ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M4.35$226.45M$1.3318.55Summit Therapeutics$700K20,099.40-$221.32M-$1.01-18.75 Which has more risk and volatility, ACAD or SMMT? ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, suggesting that its share price is 202% less volatile than the S&P 500. Do analysts prefer ACAD or SMMT? ACADIA Pharmaceuticals currently has a consensus price target of $29.65, suggesting a potential upside of 20.17%. Summit Therapeutics has a consensus price target of $33.79, suggesting a potential upside of 78.38%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryACADIA Pharmaceuticals beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.98B$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio18.5521.2474.8626.40Price / Sales4.35467.56543.78125.99Price / Cash33.5044.4425.8129.91Price / Book5.619.6413.256.28Net Income$226.45M-$53.20M$3.29B$270.38M7 Day Performance-2.84%0.44%0.47%2.70%1 Month Performance-2.61%4.26%4.60%5.99%1 Year Performance51.16%9.43%73.42%25.94% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals4.2082 of 5 stars$24.67+4.5%$29.65+20.2%+44.7%$3.98B$957.80M18.55510Positive NewsSMMTSummit Therapeutics3.0703 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$14.44B$700K-19.25110High Trading VolumeASNDAscendis Pharma A/S3.1951 of 5 stars$205.22-0.3%$244.36+19.1%+64.0%$12.56B$393.54M-39.771,017Positive NewsVTRSViatris1.6346 of 5 stars$10.48-0.2%$10.40-0.8%-14.6%$12.22B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.2799 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.91B$334.26B21.6127,811News CoverageQGENQiagen4.4411 of 5 stars$47.62+0.1%$49.69+4.4%+0.5%$10.58B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4109 of 5 stars$54.29+1.7%$63.35+16.7%+95.6%$10.38B$221.90M-13.27400Analyst ForecastMRNAModerna4.5332 of 5 stars$24.83-1.2%$42.88+72.7%-65.6%$9.66B$3.24B-3.305,800ELANElanco Animal Health2.6268 of 5 stars$19.02+3.2%$17.33-8.9%+28.0%$9.45B$4.44B22.129,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.3179 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.19B$42.28M-107.3730Positive NewsROIVRoivant Sciences3.1489 of 5 stars$12.91-0.1%$16.38+26.8%+17.9%$8.82B$23.23M-18.44860 Related Companies and Tools Related Companies Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts